Research in the News

FDA Approves First Therapy for High-Risk Neuroblastoma

FDA Approves First Therapy for High-Risk Neuroblastoma

(FDA.gov) – The U.S. Food and Drug Administration today approved Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with high-risk neuroblastoma, a type of cancer that most often occurs in young children. Neuroblastoma is a rare cancer...
Page 1 of 612345...Last »

Pin It on Pinterest

test